Genenta Science S.p.A.
Genenta Science S.p.A.
Your view on GNTA
Overview
What the company does, where it operates, and who runs it.
About Genenta Science S.p.A.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Pierluigi Paracchi
- Headquarters
- Via Olgettina No. 58, Milan, MI, IT
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Pierluigi Paracchi
- Headquarters
- Via Olgettina No. 58, Milan, MI, IT
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy.
The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Genenta Science S.p.A., and the rating behind it. GNTA last traded at $0.84; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Genenta Science S.p.A.. Starting points for Genenta Science S.p.A.: EPS -$0.29, beta 0.76 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Genenta Science S.p.A.. Genenta Science S.p.A. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Genenta Science S.p.A.. Trailing twelve-month EPS for Genenta Science S.p.A. stands at -$0.29. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Genenta Science S.p.A.. Genenta Science S.p.A. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Genenta Science S.p.A. valued side by side against its closest peers. Genenta Science S.p.A. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Genenta Science S.p.A., and how their positions are changing. At a $16.1M market value, institutional positions materially move Genenta Science S.p.A.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Genenta Science S.p.A. executives and directors. Shares of Genenta Science S.p.A. have traded between $1.95 and $10.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Genenta Science S.p.A.. Genenta Science S.p.A. is a $16.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Genenta Science S.p.A.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Genenta Science S.p.A.. Coverage tracks Genenta Science S.p.A. within Biotechnology (Healthcare). Press releases and market coverage, newest first.